Arcus Biosciences, Inc. (RCUS) Fair Value 2026

RCUS · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.7 /10

32 fundamental signals · 1 models active

Value Trap Risk

SAFE (19/100)

Quick Summary — As of 2026-08-28, Arcus Biosciences, Inc. (RCUS) trades at $29.21. QOC: 6.7/10. Value Trap Risk: 19/100 (SAFE). 1/13 models active.

Key Facts

Ticker
RCUS
Price
$29.21
Quality Score
6.7/10
Value Trap Risk
19/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

What Fair Value Does Each Model Give RCUS?

1 Intrinsic Value Models vs. Current Price ($29.21)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · Low Conviction
 $0.35 -98.8%

All Models Active

All 1 models are displayed above.

What Is Arcus Biosciences, Inc. (RCUS) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Arcus Biosciences, Inc.'s intrinsic value is estimated at $0.35, suggesting the stock is overvalued at its current price of $29.21. With 1 out of 1 models flagging downside (-98.8% vs price), the market may be pricing in unsustainable growth.

What Do the Models Say About RCUS?

1 of 13 models are currently active for RCUS. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does RCUS Rank in Biotechnology?

Among 625 Biotechnology stocks, RCUS ranks #71 by Quality of Company score. CirclFi's QOC score of 6.7/10 evaluates 32 fundamental signals. A score of 6.7 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

As a biotechnology enterprise, Arcus Biosciences, Inc. operates in a sector where pipeline depth and stage distribution is a critical driver of valuation. Investors evaluating RCUS should weigh these sector-specific dynamics alongside our model-derived fair values.

Is RCUS a Value Trap?

CirclFi's Value Trap algorithm assigns RCUS a score of 19/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Arcus Biosciences, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Arcus Biosciences, Inc.'s fundamental quality profile registers 6.7/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every RCUS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across RCUS's 1 active models, average confidence is 5%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Arcus Biosciences, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

CRNXCrinetics Pharmaceuticals, Inc.QOC 6.7FENCFennec Pharmaceuticals Inc.QOC 6.7INSMInsmed IncorporatedQOC 6.7ZLABZai Lab LimitedQOC 6.7LEGNLegend Biotech CorporationQOC 6.7MRKRMarker Therapeutics, Inc.QOC 6.7RVMDRevolution Medicines, Inc.QOC 5.4AGENAgenus Inc.QOC 4.8PKTXProtoKinetix, IncorporatedQOC 3.9EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: CRNX · FENC · INSM · ZLAB · LEGN · MRKR · RVMD · AGEN · PKTX · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to RCUS?

5 companies across all industries closest to RCUS’s Quality of Company score of 6.7/10.

XGNExagen Inc.QOC 6.7DSGRDistribution Solutions Group, Inc.QOC 6.7ALKTAlkami Technology, Inc.QOC 6.7BTEBaytex Energy Corp.QOC 6.7NVDANVIDIA CorporationQOC 10.0

Read investment analysis: XGN · DSGR · ALKT · BTE · NVDA

Where Does RCUS Sit in CirclFi's Biotechnology Rankings?

RCUS is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Arcus Biosciences, Inc.’s Valuation?

What is Arcus Biosciences, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Arcus Biosciences, Inc. (RCUS). The Quality of Company score is 6.7/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is RCUS overvalued or undervalued right now?

At $29.21, 0 of 1 active models suggest RCUS may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Arcus Biosciences, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 6.7 mean for RCUS?

Arcus Biosciences, Inc.'s QOC of 6.7/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on RCUS?

CirclFi analyzes RCUS with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is RCUS a value trap in 2026?

Arcus Biosciences, Inc.'s Value Trap score is 19/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Arcus Biosciences, Inc. (RCUS) a Quality of Company score of 6.7/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/RCUS/ · Methodology
Primary sources for this RCUS valuation
  • Financial statements: Arcus Biosciences, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001724521) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for RCUS as of ; valuations recomputed .